دورية أكاديمية

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

التفاصيل البيبلوغرافية
العنوان: Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
المؤلفون: McEvoy, Ashleigh C., Warburton, Lydia, Al-Ogaili, Zeyad, Celliers, Liesl, Calapre, Leslie, Pereira, Michelle R., Khattak, Muhammad A., Meniawy, Tarek M., Millward, Michael, Ziman, Melanie, Gray, Elin S.
المصدر: BMC Cancer; 7/9/2018, Vol. 18 Issue 1, p1-8, 8p, 2 Charts, 4 Graphs
مصطلحات موضوعية: CIRCULATING tumor DNA, TUMORS, MELANOMA, METASTASIS, POSITRON emission tomography, COMPUTED tomography, POLYMERASE chain reaction
مستخلص: Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.Conclusions: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden. [ABSTRACT FROM AUTHOR]
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:14712407
DOI:10.1186/s12885-018-4637-6